MacroGenics, Inc. (MGNX) Stock

About MacroGenics, Inc.

MacroGenics, Inc. is led by CEO Eric Blasius Risser, publicly traded since 2013.

MacroGenics, Inc. (MGNX) stock trades at $2.25 with a market capitalization of $143.33M. The stock is valued at a negative price-to-earnings (P/E) ratio of -16.25, reflecting a net loss over the last twelve months, price-to-book of 5.30, price-to-sales of 1.36. Over the past 52 weeks the stock has ranged between $1.29 and $5.08, and currently trades 55.7% below its 52-week high.

On profitability, MacroGenics, Inc. generates a return on equity (ROE) of -31.27% (negative, reflecting a net loss), return on capital employed of -17.22%, an operating margin of -40.53%, a net profit margin of -8.70%.

MacroGenics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 MacroGenics, Inc. reported revenue of $87.0M rising to $150.0M, a change of +72.4% across 10 years. Compounded, revenue has grown 8.9% a year over five years, 0.0% over three, 1.4% over the last twelve months. Net profit fell to $-75.0M.

Operating margin went from -69.3% in 2016 to -48.7% in 2025, a gain of 20.6 percentage points. The most recent net margin is -8.70%. On a trailing twelve-month basis to Jun '26, revenue is $168.0M and net profit $-14.0M.

Borrowings rose from $2.0M to $107.0M, cash from operations was $-81.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -73.3% over five years, and was -133.9% in the most recent year.

The share price itself has compounded at -27.7% a year over five years, -12.3% over three, 171.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

MacroGenics, Inc. (MGNX) — frequently asked questions